

Receptor Tyrosine Protein Kinase ERBB 4 - Global Pipeline Review, H1 2018

PUNE, MAHARASHTRA, INDIA, March 5, 2018 /EINPresswire.com/ -- WiseGuyReports.com with their unique quality of simplifying the market research study, presents a deep diving study report "Receptor Tyrosine Protein Kinase ERBB 4 - Pipeline Review, H1 2018"

Receptor Tyrosine Protein Kinase ERBB 4

Overview

Receptor Tyrosine Protein Kinase ERBB 4 (Tyrosine Kinase Type Cell Surface Receptor HER4 or Proto Oncogene like Protein c ErbB 4 or p180erbB4 or HER4 or ERBB4 or EC 2.7.10.1) - Receptor tyrosine-protein kinase erbB-4 is an enzyme that in humans is encoded by the ERBB4 gene.

Receptor tyrosine-protein kinase erbB-4 is a receptor tyrosine kinase that is a member of the epidermal growth factor receptor subfamily. it plays an essential role as cell surface receptor for neuregulins and EGF family members and regulates development of the heart, the central nervous system and the mammary gland, gene transcription, cell proliferation, differentiation, migration and apoptosis.

Click here for sample report @ <https://www.wiseguyreports.com/sample-request/3031120-receptor-tyrosine-protein-kinase-erbB-4-tyrosine-kinase>

Major Key Players:

Aslan Pharmaceuticals Pte Ltd

Boehringer Ingelheim GmbH

GamaMabs Pharma SA

Hanmi Pharmaceuticals Co Ltd

Jiangsu Kanion Pharmaceutical Co Ltd

Minerva Neurosciences Inc



WISE GUY
REPORTS

AKASH ANAND
ASST.MANAGER - BUSINESS DEVELOPMENT

✉ sales@wiseguyreports.com
☎ Ph: +1-646-843-9312 (US) Ph: +44 208 133 9349 (UK)

🌐 <https://www.linkedin.com/company/4828928>
🐦 <http://twitter.com/WiseGuyReports>
📘 <http://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Receptor Tyrosine Protein Kinase ERBB 4

Receptor Tyrosine Protein Kinase ERBB 4 Industry Major Outlook

Pharmaceutical and Healthcare latest pipeline guide Receptor Tyrosine Protein Kinase ERBB 4 - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Receptor Tyrosine Protein Kinase ERBB 4, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

Receptor Tyrosine Protein Kinase ERBB 4 (Cell Division Protein Kinase 6 or Serine/Threonine Protein Kinase PLSTIRE or CDK6 or EC 2.7.11.22) pipeline Target constitutes close to 18 molecules. Out of which approximately 17 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 2, 2, 2, 1, 8 and 1 respectively.

Receptor Tyrosine Protein Kinase ERBB 4 pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Receptor Tyrosine Protein Kinase ERBB 4 - Competitive Analysis

Key players are making innovative developments in Receptor Tyrosine Protein Kinase ERBB 4 industry. The same will help in improving the market performance. Heavy investments are made by major players in the R&D sector

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Receptor Tyrosine Protein Kinase ERBB 4.

The pipeline guide reviews pipeline therapeutics for Receptor Tyrosine Protein Kinase ERBB 4 by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Receptor Tyrosine Protein Kinase ERBB 4 therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Receptor Tyrosine Protein Kinase ERBB 4 therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Receptor Tyrosine

Protein Kinase ERBB 4.

.Continued

For Detailed Reading Please visit @ <https://www.wiseguyreports.com/reports/3031120-receptor-tyrosine-protein-kinase-erb-4-tyrosine-kinase>

About Us

Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe. Wise Guy Reports understand how essential statistical surveying information is for your organization or association. Therefore, we have associated with the top publishers and research firms all specialized in specific domains, ensuring you will receive the most reliable and up to date research data available.

Contact Us:

NORAH TRENT

Partner Relations & Marketing Manager

sales@wiseguyreports.com

www.wiseguyreports.com

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Norah Trent

WiseGuy Research Consultants Pvt. Ltd.

+1 646 845 9349 / +44 208 133 9349

[email us here](#)

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2018 IPD Group, Inc. All Right Reserved.